contract research

ready screen MTD

Innovative semi-automated procedure

Maximum Tolerated Dose Finding for Drug Discovery

Ready screen MTD is a new service for early nding the Maximum Tolerated Dose (MTD) of new drug candidates. Standarization of protocols together with semi-automated procedures allow us to provide a fast, just on time service. Your drug discovery department can now benet from the low cost and high reliability of our innovative service. Order your study using our standard protocol:

Select animal model Species / Strain Age

Mouse (Mus musculus) / CD1 10 weeks

Rat (Rattus norvegicus) / Wistar 8 weeks

Standard protocol A rst screening test is performed to determine MTD. A conrmatory test is then performed administrating the MTD determined in the rst screening.
GLP compliance Acclimatisation period Treatment Route of Administration Endpoint GLP-like in GLP facilities At least 5 days prior to administration 1 single administration Intravenous or oral (ip, id, im and others also available) Mortality or humane sacrice

First screening test Sex Experimental groups Number of animals Dosing Method Observation period Conrmatory test Sex Experimental groups Number of animals Dosing Observation period

Nulliparous non-pregnant females 4 groups corresponding to escalating doses of test item 2 per group Single administration by group. Increasing / decreasing doses for each subsequent group Interval between dosing of groups: minimum 3 days and maximum 7 days after previous group 14 days for each group

Males and nulliparous non-pregnant females 1 group 10 (5 males and 5 females) Single administration of the MTD found in rst screening test 14 days

Please inquire about GLP-compliant regulatory-level studies.